Member Info for GoSushi

Hi BV

That’s exactly how I understood it. Optimal doseb is still to be determined. But they have a lot of data.

I don’t read anything into this

These type of co culture experiments are common. It does not imply anything other than what it is.

Sorry

I should have chosen my words better

Deprioritised

Is a better choice

The reason was explained

Thorn

CC. Has explained why STS was dropped.

It was put into the too hard basket,

I can’t remember when but it was explained.

BV

That is true but we have a reasonable idea and CC has commented on Bicycle and Philogen. At present it appears Avacta is leading based on the info we have at present.

As far as science goes. I think Philogen is one of the nearest to Avacta.

GROK says…

**Summary of Yulii Bogatyrenko’s Skills and Reasons for Avacta Hire for AVA6000 Market Launch**

Yulii Bogatyrenko’s 20+ years in biopharma make him a prime candidate for Avacta to lead AVA6000’s market entry for salivary gland cancer. His key skills include:

- **Global Drug Launch Expertise**: Successfully led launches like Yaz (Bayer) and Premarin (Pfizer/Wyeth), mastering regulatory, commercial, and market access strategies critical for AVA6000’s niche SGC market.

- **Oncology and Rare Disease Acumen**: Experience as Chief Business Officer at CytoImmune Therapeutics and Carina Biotech equips him to navigate SGC’s orphan drug landscape and leverage AVA6000’s Phase 1a success (50% tumor shrinkage, 90% disease control).

- **Strategic Partnerships**: Secured high-value deals (e.g., Allergan alliance at Paratek), enabling funding and distribution for AVA6000’s Phase 2 trials and global rollout.

- **Launch Readiness**: Proven ability to align cross-functional teams (Teva, TherapeuticsMD) ensures seamless regulatory submissions and commercial planning for AVA6000’s potential 2027–2028 FDA approval.

- **Financial and Market Strategy**: NYU Stern MBA and global market experience (Teva’s emerging markets) support pricing and reimbursement strategies for AVA6000 in a $3.04B SGC market by 2031.

**Reason for Hire**: Avacta likely hired Bogatyrenko to leverage his oncology expertise, partnership-building skills, and launch readiness track record to commercialize AVA6000, ensuring strategic market entry and maximizing its potential in the high-unmet-need SGC market.

I believe his expertise is in launch readiness and this is probably the main reason for his appointment.

Isn’t it out third or 4th year of being nominated?

Philogen’s IP is very close to Avacta’s

They have also been developing a FAP cleavable exatecan and MMAE warhead

I seriously wonder what he does in full time employment?

If the company has him employed full time he should at least be able to maintain the website a bit better and respond to emails.

Of which he seems to do neither.

I imagine for STS they might want to do FAP imaging for the trials. Anyhow just repeating what CC said.

“It's obvious they have a deal lined up for STS. I don't know why everyone is sweating this so much.”

I do not agree with the above

Big clue was in the Turner Pope webinar

SGC and TNBC do not require companion diagnostics which is why they can advance quickly

STS will require companion diagnostics which is probably reason for delay

Trump talks big

But that’s all it is.!Unlikely to happen IMO.

It’s not about AVA6000 anymore

It’s about AVA6103

Go on then

Probably reincarnated as

ICECOOL

🤣🤣

A Bushveld Narcissist

Not approved for TNBC

Hi Touk

I don’t see anything in particular there that should cause doubt. Just a very matter of fact update. And everything going to plan.